# Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

> **NCT05579327** · PHASE3 · COMPLETED · sponsor: **Rare Thyroid Therapeutics International AB** · enrollment: 20 (actual)

## Conditions studied

- Monocarboxylate Transporter 8 Deficiency
- Allan-Herndon-Dudley Syndrome

## Interventions

- **DRUG:** Tiratricol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05579327
- **Lead sponsor:** Rare Thyroid Therapeutics International AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-21
- **Primary completion:** 2025-07-22
- **Final completion:** 2025-09-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579327, "Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05579327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*